We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.58B
AUM Growth
+$636M
Cap. Flow
+$643M
Cap. Flow %
17.97%
Top 10 Hldgs %
40.4%
Holding
113
New
37
Increased
33
Reduced
14
Closed
23

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$210M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$166M
3
RGEN icon
Repligen
RGEN
+$118M
4
ARWR icon
Arrowhead Research
ARWR
+$87M
5
IMCR icon
Immunocore
IMCR
+$70.6M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$191M
2
TERN
Terns Pharmaceuticals
TERN
+$144M
3
DXCM icon
DexCom
DXCM
+$84.6M
4
MRK icon
Merck
MRK
+$81.6M
5
TYRA icon
Tyra Biosciences
TYRA
+$76.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WST icon
51
West Pharmaceutical
WST
$24.5B
$18.8M 0.53%
+75,000
New +$18.7M
GEHC icon
52
GE HealthCare
GEHC
$31.5B
$17.8M 0.5%
+250,000
New +$19.7M
SGP
53
SpyGlass Pharma
SGP
$758M
$17.3M 0.48%
+666,760
New +$17.9M
ZBH icon
54
Zimmer Biomet
ZBH
$18.8B
$17.2M 0.48%
190,000
+40,000
+27% +$3.67M
MDGL icon
55
Madrigal Pharmaceuticals
MDGL
$11.1B
$16.5M 0.46%
+31,468
New +$15M
WGS icon
56
GeneDx Holdings
WGS
$2.01B
$16.1M 0.45%
+250,000
New +$22.8M
DMRA
57
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.76B
$15.5M 0.43%
+600,000
New +$15.4M
AGIO icon
58
Agios Pharmaceuticals
AGIO
$1.82B
$15.2M 0.43%
450,000
+125,000
+38% +$3.54M
ENGN icon
59
enGene Therapeutics
ENGN
$119M
$14.7M 0.41%
2,165,000
+1,110,000
+105% +$9.88M
SVRA icon
60
Savara
SVRA
$1.09B
$14.2M 0.4%
2,600,052
+994,052
+62% +$5.53M
TARS icon
61
Tarsus Pharmaceuticals
TARS
$2.68B
$14M 0.39%
+200,000
New +$14M
VYGR icon
62
Voyager Therapeutics
VYGR
$181M
$11.6M 0.32%
3,002,936
+1,527,936
+104% +$6.02M
PODD icon
63
Insulet
PODD
$11.8B
$10.6M 0.3%
+50,601
New +$12.7M
TECX
64
Tectonic Therapeutic
TECX
$527M
$10.1M 0.28%
328,000
– –
SRZN icon
65
Surrozen
SRZN
$253M
$9.86M 0.28%
+338,611
New +$8.12M
ARVN icon
66
Arvinas
ARVN
$520M
$9.6M 0.27%
+905,465
New +$11.2M
MPLT
67
MapLight Therapeutics
MPLT
$569M
$8.54M 0.24%
420,000
+35,000
+9% +$626K
FULC icon
68
Fulcrum Therapeutics
FULC
$283M
$8.44M 0.24%
1,100,000
+150,000
+16% +$1.39M
OKUR
69
OnKure Therapeutics
OKUR
$162M
$7.62M 0.21%
1,839,819
+1,204,819
+190% +$3.72M
MYGN icon
70
Myriad Genetics
MYGN
$289M
$7.42M 0.21%
1,648,000
+425,000
+35% +$2.21M
OLMA icon
71
Olema Pharmaceuticals
OLMA
$985M
$6.39M 0.18%
428,551
-1,221,449
-74% -$27.2M
AVR
72
Anteris Technologies
AVR
$806M
$6.35M 0.18%
+1,144,780
New +$6.58M
QURE icon
73
uniQure
QURE
$3.06B
$5.87M 0.16%
+358,996
New +$7.27M
CADL icon
74
Candel Therapeutics
CADL
$738M
$5.51M 0.15%
+1,125,000
New +$6.12M
PALI icon
75
Palisade Bio
PALI
$337M
$4.38M 0.12%
+2,500,000
New +$4.55M
1 2
3
4 5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Vestal Point Capital held 113 positions worth $3.58B, up 22% from $2.94B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Vestal Point Capital deployed $643M of net new capital in Q1 2026, opening 37 new positions and adding to 33 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,250,000 shares worth $165M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $144M trimmed.

  • Vestal Point Capital's largest Q1 2026 buy was Neurocrine Biosciences: 1,250,000 shares worth $165M.
  • Vestal Point Capital added most to Revolution Medicines in Q1 2026, an estimated $210M increase.
  • Vestal Point Capital's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $144M.
  • Vestal Point Capital fully exited Arcellx in Q1 2026, selling an estimated $191M.
  • Vestal Point Capital's ten largest holdings make up 40% of its $3.58B portfolio in Q1 2026.
  • Vestal Point Capital opened 37 new positions and closed 23 in Q1 2026.
  • Vestal Point Capital's portfolio value rose 22% quarter-over-quarter to $3.58B.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.